{"name":"Biohaven Ltd.","slug":"biohaven","ticker":"BHVN","exchange":"NYSE","domain":"biohaven.com","description":"Biohaven Ltd. (BHVN) is a clinical-stage neuroscience biotech company focused on developing innovative treatments for neurological disorders. The company's top drugs include rimegepant and zavegepant. Biohaven has a strong pipeline of potential treatments for various neurological conditions.","hq":"New Haven, CT","founded":2013,"employees":"~350","ceo":"Vlad Coric","sector":"Clinical-Stage Neuroscience Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"1.3B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":635065000,"netIncome":-738822000,"cash":229957000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Nurtec patent cliff ($1.4B at risk)","drug":"Nurtec","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"Qulipta patent cliff ($1.1B at risk)","drug":"Qulipta","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"BHV-2100","genericName":"BHV-2100","slug":"bhv-2100","indication":"Migraine prevention","status":"phase_2"},{"name":"BHV-4157","genericName":"BHV-4157","slug":"bhv-4157","indication":"Acute migraine treatment","status":"phase_3"},{"name":"BHV-7000","genericName":"BHV-7000","slug":"bhv-7000","indication":"Migraine prevention","status":"phase_2"},{"name":"BHV-8000","genericName":"BHV-8000","slug":"bhv-8000","indication":"Migraine prevention","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"BHV-0223","genericName":"BHV-0223","slug":"bhv-0223","indication":"Other","status":"phase_2"},{"name":"BHV3241, verdiperstat","genericName":"BHV3241, verdiperstat","slug":"bhv3241-verdiperstat","indication":"Multiple system atrophy (MSA)","status":"phase_2"}]}],"pipeline":[{"name":"BHV-0223","genericName":"BHV-0223","slug":"bhv-0223","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BHV-2100","genericName":"BHV-2100","slug":"bhv-2100","phase":"phase_2","mechanism":"BHV-2100 is a calcitonin gene-related peptide receptor antagonist.","indications":["Migraine prevention"],"catalyst":""},{"name":"BHV-4157","genericName":"BHV-4157","slug":"bhv-4157","phase":"phase_3","mechanism":"BHV-4157 is a selective serotonin 5-HT1F receptor agonist that reduces neuronal activity and neuropeptide release to treat acute migraine.","indications":["Acute migraine treatment"],"catalyst":""},{"name":"BHV-7000","genericName":"BHV-7000","slug":"bhv-7000","phase":"phase_2","mechanism":"BHV-7000 is a calcitonin gene-related peptide receptor antagonist.","indications":["Migraine prevention"],"catalyst":""},{"name":"BHV-8000","genericName":"BHV-8000","slug":"bhv-8000","phase":"phase_2","mechanism":"BHV-8000 is a calcitonin gene-related peptide receptor antagonist.","indications":["Migraine prevention"],"catalyst":""},{"name":"BHV3241, verdiperstat","genericName":"BHV3241, verdiperstat","slug":"bhv3241-verdiperstat","phase":"phase_2","mechanism":"BHV3241, also known as verdiperstat, is a small molecule inhibitor of the enzyme NADPH oxidase 2 (NOX2).","indications":["Multiple system atrophy (MSA)"],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"Biohaven Announces FDA Approval of Nurtec for Migraine Prevention","summary":"Biohaven announced that the FDA has approved Nurtec (rimegepant) for the preventive treatment of migraine in adults.","drugName":"Nurtec","sentiment":"positive"},{"date":"2022-11-07","type":"earnings","headline":"Biohaven Reports Third Quarter 2022 Financial Results","summary":"Biohaven reported its third quarter 2022 financial results, with revenue of $143.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-08-01","type":"deal","headline":"Biohaven Announces Collaboration with Eisai for Development of Zavegepant","summary":"Biohaven announced a collaboration with Eisai for the development of zavegepant, a potential treatment for migraine.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNQWV6MDAzNm9DWHFic1BiaHV5QWQ4emZHYnd5M3JSLU8wVGd0RkZNZTZIVmZKX3ZLY09lQ0Y2alRWTlcwQTU5aThheFFHa2tuV2Zodi1idXd3d3NZY2hnTzZLeVNWaGFVTTRlUTZiSkN1cUNUVXF5cEZIQThyeDhQZVRGekw5TV94Y0trV0JseDZfXzlNa0FVdFF6elg1dXZJUmNhZXBLOERncjVEV0JMdk4xWWt3Y20zSEVqbXUxcXZxOS1oZUlfM0dWWEotS2tPWFU2NnZmTmxHRGlrWTNObTNnYXp6bTBSdEpsU1BuY2lCZTFoUVJqczV0TWtfVm9vQnc?oc=5","date":"2026-02-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Oric Pharmaceuticals (ORIC) - The Globe and Mail","headline":"Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Oric Pharmaceuticals (ORIC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNWGFqUGpkb01sb1hzeWlZZEJNQWIwLV8zWlRKaDNKcVRya09ENXE3MmFEWXpKVGFUa0FacDQ3MTVEaVpiQ19BVHY3X1hoOTlkMWZ3RVB5RmRtU3BrTUhyRXlqX2QwZWRfc0ZBS3o4X1ZyVGplTTREcTFLX19nTnd0MkpucnRLMGxxem0tZF9ySWVWVnNiVjdqcnc0RGVYNURxSF9sNVI3RUVTS2EtZXRLV3kySWhJZnBoS2JQNEVVY214cFduNTFuRnVTbHFSM1BMaU5sYzJPRnhjYzVkTGVKRkRLZHdxTTMtMWJyQzlmYkFJOEVGdmkzeFdLVDNHbm51XzVLTmJ5bm5ybVhWdVM1LXlRNU1QTTFtNUNpT0pNU0ExUjctQVFxYzJ3?oc=5","date":"2026-02-20","type":"regulatory","source":"The Globe and Mail","summary":"Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (BHVN), Olema Pharmaceuticals (OLMA) and Hims & Hers Health (HIMS) - The Globe and Mail","headline":"Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (BHVN), Olema Pharmaceuticals (OLMA) and Hims & Hers Health","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxORnM3b0cybU1iMmRTbWs1NTlvSXpadDUxR2JMaEJYUEJaMWo3X29VaFpqdTZ0clFsNEVzZmIwWC0tTUkyT1lxSkVFN094QTJYNVhYczNDTXpXLTBBSXE1dUFva0Y4UVhFWWNTazNhRVJNOF9sbmV2bE1hcUZlYTVuNDEtdHJCeFRzSnByZWFuWFFZQnhJZlMzZVB6aFFiYzlEMnVEdEdlNm5KRnFRM0l2VlA1aWJGUGF5VkdiejBTZw?oc=5","date":"2025-11-12","type":"pipeline","source":"Stock Titan","summary":"Biohaven (NYSE: BHVN) prices 23,333,334-share public offering for $175M gross proceeds - Stock Titan","headline":"Biohaven (NYSE: BHVN) prices 23,333,334-share public offering for $175M gross proceeds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQNWVHdGZmajI1ZURRb1NUVTg3amp5M2NyeWZDTnZET3VkR0hLS3BaNHY5X3hxQVNIaHNCMkxpajliVzZpVllSMzhSY2pEX3NxVGZuR3dyaUhIUkM5MV9kSU5LVTJJV2ZTdFVLYkRTX2lmVGlONFR6NlZRWmNaMjQtbDhIRTFpd0lvd0tGU2lPdnJCT0Z1R0FjWGpUSHBJOFJjUVVjYWJiNWRIcHB0bG9MUVlqblNmYVdu?oc=5","date":"2025-11-05","type":"regulatory","source":"Benzinga","summary":"Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection - Biohaven (NYSE:BHVN) - Benzinga","headline":"Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection - Biohaven (NYSE:BHVN)","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOLXlNZFVSZFFNLUQtU3hOckF0dkJlMGw1alN3alpMcEZIa0x2V01mU2VYY2JCYTk0cXAxNUJnLWN2YVQ1SnFaWnlmVWVHQy05RHRnM2tKZ0c5V1Ntd243akhhOW9Nby1kd2M0WFBnUW5mSnJQbGdZWEc1TUJHd1RtcHpQMWlCQlU?oc=5","date":"2025-08-22","type":"regulatory","source":"Seeking Alpha","summary":"Biohaven rises as FDA cancels AdCom on lead drug (BHVN:NYSE) - Seeking Alpha","headline":"Biohaven rises as FDA cancels AdCom on lead drug (BHVN:NYSE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOSXZ5dTFhbmNuT045dGktcnkxOU9kdm9obFhnYnVsYkFvMUFyd0xseXR1Q3JpYkxqOEp1SmxMbkk3N3lhSmNZblRiVE1WcTktVnppSzR4Mmg2eER6MklTTGhPLTlTd2g2OWJtdzcteUlPYnZwQ1gxQVoyWFIweUh1a2NzbldfSXZidTdCV05R?oc=5","date":"2025-07-17","type":"regulatory","source":"Seeking Alpha","summary":"Biohaven: Cash Hog Awaits FDA Decision On SCA - Seeking Alpha","headline":"Biohaven: Cash Hog Awaits FDA Decision On SCA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNalVTYmFYMG9Ld2EzWF9YNjA0anRTTmlDekRPRTFkc2s2OFhtdlJvcDF1dzFhV29sQ25peEc0S2t3SGNVY1F2VzF6UVNRR0ktcjUycFpRN0ZDdy1DMXlISXZQY2gybGFoM3dzYWxhc3BFU0JRYVJnY0dFelFvVFRvNWxUTTVZdnlSVVFyTVQ0VWlZMmJ0T0luaFl5bmY4TzhKOXlUUNIBrAFBVV95cUxQU0JhdUhrYmUwcjE1Mk1OLXYtN3ZuVnB6R1NHYWs0WlJybEJpX3IyM05sMnExYmJGNXVpNTNtUVJDRC1NV3ZhYTZ3eGdTMnZGRUhxdXluVkoyeEJ1ZmxjUXhfbm9CcVkxYXNSZ2tobXBOVmZ1LXRNcHlZMVRMaEFiN1V5MjRET1c2aVMzUHFYVVRrWU44YjNVTGpPYVNIc241MVppZGtQZzJWNUhJ?oc=5","date":"2025-06-01","type":"deal","source":"Insider Monkey","summary":"Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy” - Insider Monkey","headline":"Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy”","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPeGU2S1JUNjBZRVd5QXo1Q1ZqWjVoRjdpMkQwRVh4bkhsZG5fTXRSZnpaWUZ4TWlwRHNHQ1lLb2FVWEZlR2o3Z3pBZkk1Y0RWRVctYVlld18zUEVOXzlRYmR6MXIzcW5lcEd2MlBKR1lwVHZVZEZyai1VQ0VULUF2S3QzamtsTjU2ZWkyczU2clJTRlVSeVlRa1lPakhFemJSNEhyb0FkTjVZSjN3YWlPSk5NQVkzRlFXenUyRDZEZElTTkVHd1ptc01KdlJVd1ROdjhVVktScktQdw?oc=5","date":"2025-05-12","type":"earnings","source":"PR Newswire","summary":"Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments - PR Newswire","headline":"Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZFRCeFFpZkp5ZDdSVGZKaWg3aDJNbFlkWkZoTUVqZXZ0QnR1cVhiS3ZnaXRyNVJrRjF4cWJOM3dnZUFSN2ZRUDJZM3NFYzVWLU1NcFpwQ0dEV2NMUnZuM2VFZ2lNQmpjWnhiSmJSR2FTcTdGbTE3bTNGZ2xLT0VOa1ZDVFMzR3lSRVZYb1VvQmoyYk1MS295c3pBd2g3N2hiNmZzUm1sLTd2azRPak1kY0VzTFViYkoyNlZ5SmtXM1c?oc=5","date":"2025-04-28","type":"pipeline","source":"PR Newswire","summary":"Biohaven Announces Investment up to $600 Million by Oberland Capital - PR Newswire","headline":"Biohaven Announces Investment up to $600 Million by Oberland Capital","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQU1ctMHBYSkRGd1hreGJJdEYxVXNGMkIwSjMxTWYxY2Z4clBqTXkyQklLWWU1bTRYdTJ3XzZSeXdJME1oRXF0Z3k5dnBnLTd4UnowOTgtanpfbnJKVFR2bk56amtSdEw4Y1l3TmxTR0RPTTN0aWdLaW50Sm1ON1hON2NSNl8wcTdRUVhWUnVPOTJ1eThEc0VB?oc=5","date":"2024-08-08","type":"pipeline","source":"Yahoo Finance","summary":"Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? - Yahoo Finance","headline":"Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Inve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE1oaVM2aTVpbDlwNm9pZjc0RzNDSkY3UVB2NlpEaWJ2WDIzOFZBMFJaeVRaRFU0SzhiMF8xLUgtN21yZVAxTmpCWWlTcndBdTN3?oc=5","date":"2024-03-03","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPV0VNc2ViZkV1Qjd6M05NNHRXQ25ILXFuVTl4MkFxM2kzU1BVREpwaXRxbUp5RURsdW94dzQzTDhhRlA0UWFGb25vQ0ZVWGpFQ3BvbzEzbTVBaVFud3YyelViSVZ6Vm5DM19PZVVjVEdtZkNJSE1SUURPUVR5ZHY0OHoybkc?oc=5","date":"2022-10-04","type":"pipeline","source":"The Motley Fool","summary":"Why Biohaven Stock Is Soaring Today - The Motley Fool","headline":"Why Biohaven Stock Is Soaring Today","sentiment":"neutral"}],"patents":[{"drugName":"Nurtec","drugSlug":"rimegepant","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Qulipta","drugSlug":"atogepant","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1100000000}],"drugCount":6,"phaseCounts":{"phase_2":5,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Allergan","Eli Lilly","Pfizer"],"therapeuticFocus":["Migraine","Neurological Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":635065000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-738822000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":229957000,"cashHistory":[],"totalAssets":451447000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}